Voyager Therapeutics to Present Preclinical Data from Vectorized Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting

by NASDAQ Market News November 16, 2021

NASDAQ Market News
Click here to email author

Clearside Biomedical Features FDA-Approved XIPERE™ in Multiple Presentations at the American Academy of Ophthalmology 2021 and American Uveitis Society Meetings

Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation Cohorts

Ads